QYuns Therapeutics

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about QYuns Therapeutics
, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about QYuns Therapeutics
please access flcube.com

Company Drug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

The US Food and Drug Administration (FDA) announced that it has approved AbbVie's (NYSE: ABBV) tavapadon for the treatment of Parkinson's disease, under the brand name Juvmo. Regulatory Milestone ItemDetailAgencyUS…

September 28, 2026

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

September 28, 2026

$Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies$

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

September 28, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Company Deals

QYuns Therapeutics

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Empowering Chinese Pharma’s Global Expansion

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease

Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis

Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin

Jiangsu QYuns Therapeutics and Huadong Medicine Partner on QX005N Injection Development and Promotion

Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N

Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N

About Company